Orphan drug designation in the European Union for IPH4102
Completion of target enrollment in the phase II EffiKIR trial
Number of shares and voting rights of Innate Pharma as at June 30, 2014
Innate Pharma raises 50 million euros in a capital increase subscribed by specialist institutional investors
Innate pharma launches a capital increase to raise up to 15% of current capital
Innate Pharma announces revenue for the first three months of 2014 and updates on its cash Position
Highlights from Innate Pharma's R&D update
Number of shares and voting rights of Innate Pharma as at April 4, 2014
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
Outcome of Annual General Meeting of March 27, 2014
